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Abstract
Rationale In addition to the negative and positive symptoms
of schizophrenia, cognitive deficits, including prefrontal cor-
tical dysfunction, are now recognized as core features of this
disorder. Compounds increasing the NMDA receptor function
via the strychnine-insensitive glycine receptors have been
proposed as potential antipsychotics. Depending on the ambi-
ent concentrat ions of glutamate and glycine, 1-
aminocyclopropanecarboxylic acid (ACPC) behaves as either
a partial agonist or a functional antagonist at the strychnine-
insensitive glycine receptors.
Objectives We investigated the procognitive and
antipsychotic-like effects of ACPC in rats treated with phency-
clidine (PCP) or ketamine (KET), compounds that produce
psychotic-like symptoms in humans and laboratory animals.
Methods Cognitive effects were investigated in the novel
object recognition (NOR) and attentional set-shifting tests
(ASST). In addition, the effects of ACPC were investigated
in PCP-induced hyperactivity, conditioned avoidance re-
sponse (CAR), and prepulse inhibition (PPI) tests. The effects
on attention and impulsivity were measured in the five-choice
serial reaction time task (5-CSRTT).
Results ACPC (200–400 mg/kg) inhibited memory fading in
naive rats and like clozapine prevented PCP- and KET-
induced amnesia in the NOR. In naive animals, ACPC at
400 but not 200 mg/kg enhanced cognitive flexibility in the
ASST, as the animals required fewer trials to reach the criteria
during the extra-dimensional phase. In contrast, ACPC did not
affect PCP-induced hyperactivity, CAR, and PPI as well as
attention and impulsivity in the 5-CSRTT.
Conclusion The present study demonstrates that ACPC en-
hanced both object recognition memory and cognitive flexi-
bility dependent on the prefrontal cortex, but did not affect
impulsivity nor exhibit an antipsychotic-like profile.
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Introduction
Glutamatergic transmission through the N-methyl-D-aspartate
receptor (NMDAR) receptor subtype plays a critical role in
neuroplasticity. Furthermore, it has been suggested that an
increase in NMDAR activity may lead to cognitive enhance-
ment (Danysz and Parsons 1998). Augmentation of gluta-
matergic neurotransmission may also produce antipsychotic
effects; for a review, see Hashimoto et al. (2013). Conversely,
NMDA antagonists such as phencyclidine (PCP) and keta-
mine (KET) elicit positive, negative, and cognitive psychotic-
like symptoms in normal volunteers and produce a recrudes-
cence of psychotic symptomatology in patients (Javitt and
Zukin 1991; Krystal et al. 1994; Jentsch and Roth 1999).
Activation of the NMDAR requires binding of both gluta-
mate and its co-agonist, glycine, a small nonessential amino
acid (Johnson and Ascher 1987). Since an enhancement of
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glutamatergic tone by direct (orthosteric) NMDA receptor
agonists does not appear to be a feasible therapeutic strategy,
a more practical approach is to enhance the function of
strychnine-insensitive glycine sites. This can be done using
full and partial glycine agonists or by enhancing glycine
availability at the synaptic cleft by inhibiting reuptake through
glycine transporter 1 (GlyT1; (Raiteri and Raiteri 2010)). The
rationale for this approach relies on the assumption that
strychnine-insensitive glycine sites at the NMDAR are not
saturated under physiological conditions (for a review, see
(Danysz and Parsons 1998)).
Consistent with this approach, both antipsychotic and
procognitive effects have been demonstrated for compounds
increasing transmission at glycine sites. Almost 30 years ago,
glycine itself was shown to reduce PCP-induced hyperactivity
in mice (Toth and Lajtha 1986). GlyT1 inhibitors that elevate
ambient glycine concentrations reversed or attenuated
NMDAR antagonist-induced abnormally persistent latent inhi-
bitions (Lipina et al. 2005; Black et al. 2009) and deficits of
prepulse inhibition (PPI) (Lipina et al. 2005; Depoortere et al.
2005; Boulay et al. 2008). In the latter paradigm, the NMDA
receptor antagonist ketamine dose-dependently reduces PPI
(Swerdlow et al. 1998). While the prototypic antipsychotic
haloperidol is inactive per se and does not reverse ketamine-
induced reduction of PPI, chlorpromazine, seroquel, and cloza-
pine are active in this model. In general, reversal of NMDA
antagonist-induced decreases in PPI is considered an
antipsychotic-like effect (see Geyer et al. (2001) for the review).
Other studies demonstrated that D-serine, a full agonist at
the strychnine-insensitive glycine sites, enhanced social mem-
ory in rats (Shimazaki et al. 2010) and that D-cycloserine, a
partial agonist at the strychnine-insensitive glycine sites, fa-
cilitated learning and memory in rats (Monahan et al. 1989).
Inhibitors of GlyT1 have also demonstrated procognitive ef-
fects in preclinical models of schizophrenia. For instance,
SSR-103800 reversed PCP-induced impairment of short-
term episodic-like memory in the object recognition task
(Boulay et al. 2008), whereas NSFP improved dizocilpine
(MK-801)-disrupted social memory (Shimazaki et al. 2010).
Recent data from this laboratory (Nikiforuk et al. 2011) dem-
onstrated that SSR-504734, a non-sarcosine GlyT1 inhibitor,
enhanced cognitive performance in the attentional set-shifting
test (ASST), a measure of prefrontal flexibility that is com-
promised in schizophrenic patients (Lewis and Gonzalez-
Burgos 2008) as well as in healthy volunteers (Krystal et al.
1994) and rats treated with NMDAR antagonists (Stefani et al.
2003; Egerton et al. 2005; Nikiforuk et al. 2010).
In clinical studies, glycine (Javitt et al. 1994), D-serine, and
sarcosine have been shown to ameliorate symptoms of schizo-
phrenia in medicated patients (Lane et al. 2005; Tsai and Lin
2010). Meta-analyses indicate that glycine, D-serine, and
sarcosine are more effective than D-cycloserine in improving
the overall psychopathology in schizophrenic patients
receiving antipsychotic drugs (Heresco-Levy and Javitt
2004; Tuominen et al. 2005; Tsai and Lin 2010), suggesting
a relatively narrow therapeutic window for partial agonists at
the glycine sites (Hashimoto et al. 2013).
1-Aminocyclopropanecarboxylic acid (ACPC) is a high-
affinity partial agonist at the strychnine-insensitive glycine
sites (Marvizon et al. 1989) that exhibits anticonvulsant
(Witkin and Tortella 1991), neuroprotective (Von Lubitz
et al. 1992; Fossom et al. 1995), anxiolytic (Trullas et al.
1989), anti-addictive (Kolesnikov et al. 1994) and
antidepressant-like (Trullas and Skolnick 1990; Trullas et al.
1991; Papp and Moryl 1996) effects in rats and mice. This
broad range of pharmacological effects is reminiscent of
NMDA antagonists.
However, in contrast to NMDA receptor antagonists acting
at other loci and the full antagonist of the glycine site 7-chloro-
kynurenic acid that impair spatial learning (Bannerman et al.
1997; Carli et al. 2001), the functional NMDA/glycine recep-
tor antagonist ACPC does not impair memory or learning
processes in a step-through avoidance (Faiman et al. 1994).
Conversely, preclinical studies demonstrated that ACPC facil-
itates spatial learning in senescent rats (Popik and Rygielska
1999) and in mice tested in a single-trial inhibitory avoidance
learning both in naive animals and following administration of
a variety of amnestic agents (Viu et al. 2000). These properties
make ACPC a particularly interesting molecule to investigate
both in tests addressing cognitive deficits observed in schizo-
phrenia (NMDAR antagonist-disturbed conditions, prefrontal
cognitive flexibility) as well as in procedures used to detect
potential antipsychotic activity (PCP-induced hyperactivity,
CAR, PPI). Here, ACPC was also tested in the five-choice
serial reaction time task (5-CSRTT), a procedure that permits
the simultaneous examination of multiple aspects of attention-
al performance (Bari et al. 2008) including the accuracy of
attentional processes and impulsivity. While NMDAR antag-
onists (e.g., MK-801, PCP) have been demonstrated to disrupt
attentional performance and/or increase impulsivity (reviewed
in (Amitai and Markou 2010)), the effects of glycinergic
compounds have not been widely assessed in this task.
Materials and methods
Animals
Male Sprague-Dawley rats (Charles River, Germany)
weighing 250–280 g on arrival were used in this study. Ani-
mals were initially group-housed (five rats/cage) in a
temperature- (21±1 °C) and humidity- (40–50 %) controlled
colony room under a 12/12-h light/dark cycle (lights on at
06:00 h). Rats were allowed to acclimatize for at least 7 days
before the start of the experimental procedures. In the ASST,
rats were individually housed with mild food restriction (15 g
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of food pellets per day) and ad libitum access to water for
1 week prior to testing. For the 5-CSRTT, rats were group-
housed (four rats/cage) with mild food restriction (15 g of food
pellets per day). Behavioral testing was performed during the
light phase of the light/dark cycle. The experiments were
conducted in accordance with the NIH Guide for the Care
and Use of Laboratory Animals and were approved by the
Ethics Committee for Animal Experiments, Institute of Phar-
macology. All rats were used only once, and each experiment
was carried out on a separate cohort of animals.
Novel object recognition test (NOR)
The protocol described earlier (Nikiforuk et al. 2013) was
adapted from the original work of Ennaceur and Delacour
(1988). At least 1 h before the start of the experiment, the rats
were transferred to the experimental room for acclimation.
Animals were tested in a dimly lit (25 lx) open-field apparatus
made of a dull gray plastic (66×56×30 cm). After each
measurement, the floor was cleaned and dried. The procedure
consisted of a 5-min habituation to the arena without any
objects, 24 h before the test. The testing comprised two trials
separated by an inter-trial interval (ITI). To test the memory
improvement in naive animals, an ITI of 24 h was chosen. To
test the memory improvement in either PCP- or KET-
disturbed conditions, a 1-h ITI was chosen.
During the first (familiarization, T1) test period, two iden-
tical objects (A1 and A2) were presented in the opposite
corners of the arena, approximately 10 cm from the walls.
Following T1, the objects were cleaned with water containing
a dishwashing agent and dried. In the second trial (recogni-
tion, T2) one of the objects was replaced by a novel one (A =
familiar and B = novel). Both trials lasted for 3 min. After T1,
animals were returned to their home cages. The objects used
were a 250-ml glass beaker (diameter of 8 cm, height of
14 cm) filled with gravel (350 g) and a 250-ml plastic bottle
(6×6×13 cm) filled with sand (450 g). The location of the
novel object in T2 was randomly assigned for each rat. Ex-
ploration of an object was defined by rats looking, licking,
sniffing, or touching the object, but not leaning against, stand-
ing, or sitting on the object. The exploration time of the
objects was measured using the Any-maze® tracking system
(Stoelting Co., IL, USA). Based on the exploration time (E) of
the two objects, a discrimination index was calculated in
accordance with the formula discrimination index
(DI)=(EB–EA)/(EA+EB), where EA is defined as the time
spent exploring the familiar object and EB is the time
spent exploring the novel object, respectively.
Attentional set-shifting test (ASST)
Testing was conducted in a modified wire rat housing cage
(42×32×22 cm) with a white plywood wall dividing half of
the length of the cage into two sections. During testing, one
ceramic digging pot (diameter of 10 cm, height of 2 cm) was
placed in each section. Each pot was defined by a pair of cues
along with two stimulus dimensions (the digging media and
odors, as described in details by Nikiforuk et al. (2010)). To
mark each pot with a distinct odor, 5 μl of a flavoring essence
(Dr. Oetker®, Poland) was applied to a small piece of blotting
paper fixed to the external rim of the pot immediately prior to
use. A different pot was used for each combination of digging
medium and odor; only one odor was ever applied to a given
pot. The bait (one-third of a Honey Nut Cheerio, Nestle®) was
placed at the bottom of the “positive” pot and buried in the
digging medium.
The procedure was adapted from Birrell and Brown (2000)
and entailed three testing days for each rat, as described in
details elsewhere (Nikiforuk et al. 2011). In simple discrimi-
nation (SD) involving only one stimulus dimension, the pots
differed along one of the two dimensions (i.e., a digging
medium). For compound discrimination (CD), a second, irrel-
evant, dimension (i.e., an odor) was introduced, but the correct
and incorrect exemplars of the relevant dimension remained
constant. For the reversal of this discrimination (Rev 1), the
exemplars and relevant dimension were unchanged, but the
previously correct exemplar was now incorrect and vice versa.
The intra-dimensional (ID) shift was then presented, compris-
ing new exemplars of both the relevant and irrelevant dimen-
sions with the relevant dimension remaining the same as
previously. The ID discrimination was then reversed (Rev 2)
so that the formerly positive exemplar became the negative
one. For the most essential, extra-dimensional (ED) shift, a
new pair of exemplars was again introduced, but this time, a
relevant dimension was also changed. Finally, the last phase
was the reversal (Rev 3) of the ED discrimination problem.
The exemplars were always presented in pairs and varied so
that only one animal within each treatment group received the
same combination. The following pairs of exemplars were
used: pair 1: odor: lemon vs. almond, medium: cotton wool
vs. crumpled tissue; pair 2: odor: spicy vs. vanilla, medium:
metallic filler vs. shredded paper; and pair 3: odor: rum vs.
cream, medium: clay pellets vs. silk. Our previous study
demonstrated that there were no differences in the perfor-
mance of rats shifted from odor to medium and from medium
to odor (Nikiforuk et al. 2010). Therefore, in an attempt to
simplify the experimental design, the order of discrimination
was always the same (i.e., from digging medium to odor). The
assignment of each exemplar in a pair as being positive or
negative at a given phase and the left-right positioning of the
pots in the test apparatus on each trial were randomized.
Spontaneous and PCP-induced hyperactivity
Spontaneous and PCP-induced locomotor activity was mea-
sured automatically in Opto-Varimex-4 Auto-Tracks
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(Columbus Instruments, OH, USA) located in sound-
attenuated and ventilated boxes. The Auto-Track System
sensed the motion with a grid of infrared photocells (16 beams
per axis) surrounding the arena.
Conditioned avoidance response (CAR)
The training and the testing were performed in four shuttle
boxes (Med Associates, Inc., USA). Each box (44×21×
18 cm) was housed in ventilated, sound-isolated cubicles
and was divided in two equal-sized compartments by guillo-
tine doors. The rats were allowed to move freely from one
compartment to another at any time. The position of the
animal was tracked by eight photocells in each of the boxes.
A cue light was situated on the wall opposing the compart-
ment entry.
The sessions were started by presenting the conditioned
stimulus (CS; the light) for 10 s, followed by an unconditioned
stimulus (UCS; continuous foot shock of 0.37 mA) for the
maximum duration of 10 s. The procedure was repeated with
20 trials daily with an intra-trial interval of 20–40 s. If a rat
moved from one compartment to another within 10 s of CS
presentation, it avoided the foot shock, and this shuttle re-
sponse was recorded as avoidance. If the rat remained in the
compartment for more than 10 s and made a crossing upon
receiving the foot shock, this response was recorded as an
escape. If the rats did not respond either during the 10 s of CS
or by 10 s of UCS, the trial was terminated and escape failure
was recorded. It is known that compounds displaying antipsy-
chotic activity selectively inhibit avoidance response without
affecting escapes and failures (Wadenberg and Hicks 1999).
About 12–15 training sessions, lasting for 2–3 weeks, were
needed to train the animals to the stable avoidance level of
above 80 % in two consecutive days. The rats fulfilling these
criteria (~60 %) were given different doses of ACPC or
clozapine as a positive control. Due to the nature of the test,
allowing for repeated testing (Wadenberg and Hicks 1999),
animals were drug tested up to three times with a 7-day drug-
free period between tests according to a randomized design
(Wadenberg et al. 1997).
Prepulse inhibition of the acoustic startle response (PPI)
The PPI procedure was adopted from a published protocol
(Auclair et al. 2006). Rats were subjected to two pretest
sessions: an afternoon session on the day before testing and
a morning session on the test day (Fijal et al. 2014). We used a
startle apparatus (Med Associates, Inc., USA) consisting of
acrylic animal holders with a grid floor made of stainless bars,
mounted onto a startle platform placed in a ventilated, sound-
attenuated chambers (Nikiforuk et al. 2013). Acoustic stimuli
were generated by two speakers: a background-noise speaker
and a stimulus speaker, placed at the back of the chamber,
7 cm from an animal holder. Startle responses were detected
and transduced by the load cell, then digitized and stored by
Startle Reflex Software (Med Associates, version 5).
Each session started with a 5-min acclimatization period. A
62-dB background white noise was continuously presented
once animals were placed in the test chambers. The following
types of acoustic stimuli were used in the test protocol: pulse
alone [intensity, 120 dB; duration, 40 ms, (P)], pulse preceded
by an acoustic prepulse of intensities 70, 73, and 76 dB [dura-
tion, 20ms, (PP)], applied 100ms before the pulse (P), prepulse
alone [intensities, 70, 73, and 76 dB; duration, 20 ms], and a
null period. The session consisted of three blocks. During the
first block, the animals were exposed to ten pulse-alone trials.
During the second block, the following trials were presented in
random order: pulse alone, pulse preceded by each prepulse,
along with one repetition of each prepulse alone, and four null
trials. The inter-trial interval was 20 s. The third block consisted
of ten pulse-alone trials. Earlier experiments in this laboratory
demonstrated that four presentations of each trial type—as
compared to the more common 10 presentations protocol—
consistently revealed the antipsychotic-like activity of cloza-
pine (5 mg/kg IP, given 25 min before the test (Fijal et al.
2014)). Therefore, in the present experiments, we used four
repetitions of each trial type.
Five-choice serial reaction time task (5-CSRTT)
Two separate cohorts were trained in the 5-CSRTT. Eight 5-
CSRTT operant chambers (Med Associates, Inc., USA), mea-
suring 56×56×40.5 cm, were housed in sound-attenuated,
ventilated cubicles. In each chamber, an array of five square
nose-poke holes (2.5×2.5×2.5 cm) was arranged on a curved
panel and raised 2.5 cm from the grid floor. Each hole was
equipped with an infrared detector and a yellow stimulus light
at its rear. The food magazine, equipped with photocell beams
and light, was located on the opposite wall. Food pellets
(45 mg, Bio-Serv, USA) were delivered via a dispenser con-
nected to the food magazine. A house light was located 17 cm
above the top edge of the foodmagazine. Online control of the
apparatus and data collection was performed using MED-PC
(Med Associates, Inc., USA).
In the initial training phase of magazine training, rats had to
learn that food pellets were available in the magazine. On the
first day, rats were habituated to the operant chambers for
15 min. During this habituation session, the food magazine
was filled with several pellets. Next, rats were given magazine
training sessions, in which every head entry into a food
magazine resulted in a pellet delivery. Once all rats ate 100
food pellets within a session (which usually took one–two
sessions), the training proceeded to the next stage.
In the next phase of pretraining, rats had to learn to asso-
ciate a nose-poke response into an illuminated hole with a
pellet delivery. All of the five holes were illuminated, and a
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response in any aperture was rewarded by a food pellet. This
procedure was continued daily until rats obtained 100 pellets
within a session.
In the 5-CSRTT training and testing phase, each session
began with the illumination of the house light and delivery of a
food pellet. A nose poke into the magazine tray initiated the
first trial, which consisted of an inter-trial interval (ITI)
followed by the random illumination of one of the five holes
for a fixed interval (stimulus duration, Sd). If a nose poke was
registered in the illuminated hole before the end of the limited
hold (Lho, i.e., a fixed interval after Sd), a pellet was delivered
and a correct trial was registered. An incorrect response or a
failure to respond within the required period (omission) re-
sulted in a time-out (TO) period, in which the house light was
extinguished. Responding to any of the five holes during the
ITI (premature response) also resulted in a TO. For the first
session of training, the stimulus duration and limited hold
periods were both set at 60 s and the ITI and TO were 2 s.
These variables were gradually altered during training, so the
final test parameters were as follows: Sd=1 s, Lho=5 s, ITI=
5 s, TO=5 s. Rats had been trained until they reached the
criteria of accuracy >70 %, omissions <30 %, and stable
baseline performance over five consecutive sessions (that took
approximately 60 training sessions). Each session lasted for
30 min or until 100 trials had been completed. During testing
sessions, all rats completed 100 trials within 30 min.
Drugs
1-Aminocyclopropanecarboxylic acid (ACPC) kindly donat-
ed by Dr. M-L Maccecchini, phencyclidine hydrochloride
(Sigma-Aldrich, USA), ketamine (aqueous solution
(115.34 mg/ml; Biowet Pulawy, Poland)), and MK-801 ma-
leate (Abcam Biochemicals, Cambridge, UK) were dissolved
in distilled water. Clozapine (Abcam Biochemicals, Cam-
bridge, UK) was dissolved in 0.1 N HCl supplemented with
distilled water to the appropriate volume (final pH=5.0–6.0).
All compounds were administrated in a volume of 1 ml/kg,
except ACPC at 400 mg/kg which was administered in a
volume of 2 ml/kg due to solubility limitations.
Drug administration
The doses, routes, and times of administration of compounds
that maximized the chance to observe a given effect were
selected based on previously published data (Popik and
Rygielska 1999; Nikiforuk et al. 2010, 2011, 2013; Fijal
et al. 2014).
Novel object recognition test (NOR)
In the naive animals, ACPC was administered IP, 30 min
before familiarization phase (T1). Separate groups of animals
tested in the NMDAR antagonist-disturbed conditions, re-
ceived ketamine (20 mg/kg, IP) and phencyclidine (5 mg/kg,
IP) 45 min before T1, and either ACPC or clozapine was
administered 30 min before ketamine, PCP, or vehicle.
Attentional set-shifting test (ASST)
ACPC (200–400 mg/kg IP) was administered 30 min before
the test.
Spontaneous and PCP-induced hyperactivity
Separate groups of animals were administered ACPC, cloza-
pine, or their vehicles IP, 30 min before being placed individ-
ually into the auto-tracks for 30min of spontaneous locomotor
activity measurement. Thereafter, the same rats were removed
from the boxes and injected with PCP at a dose of 5 mg/kg
(SC), and then, the PCP-induced locomotor activity was mea-
sured for the following 15–45 min.
Conditioned avoidance response (CAR)
ACPC (200–400 mg/kg IP) and clozapine (1–6 mg/kg, IP)
were administered 30 and 60 min before the test, respectively.
Prepulse inhibition of the acoustic startle response (PPI)
Naive rats received ACPC (100–400 mg/kg IP) 15 min before
the test. In ketamine-disturbed conditions, ACPC (200–
400 mg/kg, IP) and ketamine (10 mg/kg SC) were adminis-
tered 15 and 5 min, respectively, before the test.
Five-choice serial reaction time task (5-CSRTT)
ACPC (200–400 mg/kg, IP) and MK-801 (12.5–50 μg/kg,
SC) were administered 30 and 10 min before the test,
respectively.
Data analysis
Data were analyzed using IBM/SPSS 21 for Windows. The
alpha value was set at P<0.05. The homogeneity of variance
was measured with Levene’s test.
Novel object recognition test (NOR)
Discrimination index (DI) data were analyzed using one-way
ANOVAs with drug dose as between-subject factor. Sidak’s
test was used as a post hoc test (Howell 1997).
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Attentional set-shifting test (ASST)
The number of trials required to achieve the criterion of six
consecutive correct responses was recorded for each rat and
for each discrimination phase. The data were assessed by two-
way ANOVA with ACPC dose as a between-subject factor
and discrimination phase (SD, CD, Rev 1, ID, etc.) as a
within-subject factor. Sidak’s test was used as a post hoc test.
Spontaneous and PCP-induced hyperactivity
The activity data collected every 5 min are presented as area
under curve of the total distance traveled, in centimeter. The
measurement of the first 30 min indicates ACPC- or clozapine-
induced effects on spontaneous locomotor activity. The second
period (measured in the same animals 15–45 min following
PCP administration) indicates drug-induced alteration of PCP-
induced hyperactivity (Gleason and Shannon 1997). Separate
ANOVAs followed by Dunnett’s multiple comparison tests
were used to assess the effects of compounds on activity.
Conditioned avoidance response (CAR)
Separate one-way ANOVAs, followed by Tukey’s post hoc
tests, were used to assess the effects of ACPC and clozapine
on the percentage of conditioned avoidance responding and of
escape failures.
Prepulse inhibition of the acoustic startle response (PPI)
Themean response amplitude for pulse-alone [P] and prepulse
+ pulse [PP] trials was computed for each rat, and PPI was
determined according to the formula: PPI (%)=[(P−PP)/P]×
100. Percentage PPI data were analyzed using two-way
ANOVAs with the between-subject factors of drug treatment
and prepulse intensity as a within-subject factor followed by
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Fig. 1 (a) ACPC improves
object recognition memory in the
novel object recognition (NOR)
test at a long (24 h) inter-trial
interval (ITI) in naive animals
(**P<0.01, ***P<0.001 vs.
vehicle; N=10 rats per dose). (b)
At a short (1 h) ITI, ketamine
(20 mg/kg) disturbs object
recognition memory
(***P<0.001 vs. vehicle) and
400 mg/kg of ACPC prevents
ketamine-induced disturbance
(###P<0.001 vs. vehicle +
ketamine); N=9–10 rats per dose.
(c) At a short (1 h) ITI, PCP
(5 mg/kg) disturbs object
recognition memory
(***P<0.001 vs. vehicle) and
400 mg/kg, but not 200 mg/kg of
ACPC, prevents PCP-induced
disturbance (##P<0.01 vs.
vehicle + PCP); N=8–10 rats per
dose. (d) A similar procognitive
effect of 1 mg/kg of clozapine,
which at a short (1 h) ITI, prevents
from PCP-induced disturbance
(###P<0.001 vs. vehicle + PCP);
N=9–11 rats per dose. Values
represent the mean (±SEM) of
discrimination index
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Fisher's protected LSD. Pulse amplitude values, (calculated as
the average response to all of the pulse-alone trials) were
subjected to one-way ANOVAs.
Five-choice serial reaction time task (5-CSRTT)
The following parameters were recorded in each session:
percent of accuracy (number of correct responses divided by
the sum of correct and incorrect responses×100), number of
premature responses (total number of responses performed
during the ITIs), omissions (total number of trials omitted
during a 100-trial session), correct response latency (time
from the stimulus onset to a correct response), reward latency
(time from a correct response to the retrieval of food from the
magazine), as well as perseverant responses (total number of
responses emitted after a correct response has been made).
The data regarding the accuracy (the main measure of
performance) and the number of premature responses (the
main measure of impulsivity) are presented on Fig. 6; the
other data are presented in Table 3. Separate one-way
ANOVAs, followed by Tukey’s post hoc tests, were used to
assess the effects of ACPC and MK-801 on the outcome of 5-
CSRTT.
Results
Novel object recognition test (NOR)
As shown in Fig. 1a, ACPC dose-dependently improved
object recognition memory in naive rats at the long (24 h)
inter-trial interval: F(2.27)=25.35, P<0.001. At 1 h inter-trial
interval, ketamine (20 mg/kg) produced an impairment of
object recognition memory, which was alleviated by
Table 1 The effects of treatments
on the exploration of objects A1
and A2 used during test 1 in the
novel object recognition test
Treatment (N) Object A1 exploration (s) Object A2 exploration (s)
ITI=24 h, undisturbed conditions
Vehicle (10) 12.66±1.07 11.70±1.13
ACPC 200 mg/kg (10) 10.84±0.67 11.25±1.20
ACPC 400 mg/kg (10) 11.31±1.38 12.15±1.08
Statistics of two-way mixed-design ANOVA Treatment: F(2.27)=0.33; NS
Object: F(1.27)=0.02; NS
Treatment × object: F(2.27)=0.88; NS
ITI=1 h, ketamine disturbed
Vehicle (10) 8.37±0.78 9.43±0.62
VEH+KET 20 mg/kg (9) 10.38±0.95 12.09±1.20
ACPC 400+KET 20 mg/kg (10) 9.15±0.68 10.58±1.06
Statistics of two-way mixed-design ANOVA Treatment: F(2.26)=2.50; NS
Object: F(1.26)=5.44; P<0.05
Treatment × object: F(2.26)=0.90; NS
ITI=1 h, PCP disturbed
Vehicle (8) 10.83±0.73 9.75±0.59
VEH+PCP 5 mg/kg (9) 9.23±1.13 9.61±0.82
ACPC 200+PCP 5 mg/kg (10) 8.85±1.27 8.73±1.09
ACPC 400+PCP 5 mg/kg (10) 9.89±1.46 10.01±0.94
Statistics of two-way mixed-design ANOVA Treatment: F(3.33)=0.50; NS
Object: F(1.33)=0.08; NS
Treatment × object: F(3.33)=0.26; NS
ITI=1 h, PCP disturbed
Vehicle (9) 8.76±1.08 8.54±0.52
VEH+PCP 5 mg/kg (9) 7.31±1.00 7.60±1.13
Clozapine 1+PCP 5 mg/kg (11) 6.95±1.18 9.08±0.86
Statistics of two-way mixed-design ANOVA Treatment: F(2.26)=0.53; NS
Object: F(1.26)=1.03; NS
Treatment × object: F(2.26)=1.05; NS
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400 mg/kg of ACPC: F(2.26)=41.81, P<0.001 (Fig. 1b). At
200 and 400 mg/kg, ACPC also prevented PCP-induced
impairment of object recognition memory: F(3.33)=14.82,
P<0.001 (Fig. 1c). The “positive” control, clozapine
(1 mg/kg), similarly prevented an impairment of object rec-
ognition memory in PCP-induced disturbed conditions:
F(2.26)=42.76, P<0.001 (Fig. 1d). Table 1 shows that the
compounds used did not affect the exploration of objects
during familiarization phase (T1).
Attentional set-shifting test (ASST)
Figure 2 shows that the animals required more trials to the
criterion at the ED phase than at the ID phase, suggesting that
the presently used experimental conditions allowed for build-
ing an attentional set. ACPC reduced the number of trials to
criterion at the ED phase (Fig. 2) at the dose of 400 but not
200 mg/kg, suggesting an improvement of cognitive flexibil-
ity. Two-way ANOVA demonstrated a significant interaction
between the dose and the phase of discrimination: F(12.90)=
3.85, P<0.001.
Spontaneous and PCP-induced hyperactivity
Figure 3a demonstrates that clozapine inhibited spontaneous
activity at the dose of 3 mg/kg (F(3.30)=4.94, P<0.005). In
addition, clozapine attenuated PCP-induced hyperactivity al-
ready at the dose of 1 mg/kg (F(3.30)=4.23, P<0.025,
Fig. 3b), a characteristic for antipsychotic-like activity. In
contrast, ACPC affected neither spontaneous activity
(F(3.39)=0.1, Fig. 3c) nor PCP-induced hyperactivity
(F(3.39)<1, Fig. 3d).
Conditioned avoidance response (CAR)
ACPC did not affect conditioned avoidance responding:
F(2.16)=0.49, NS. In contrast, clozapine (3 and 6 mg/kg) re-
duced avoidance responses, indicative of antipsychotic-like ef-
ficacy, F(3.42)=26.85, P<0.001. Clozapine did not affect es-
cape failures (F(3.42)=1.10, NS) indicating that at these doses,
it does not produce sedation or motor side effects (Fig. 4).
Prepulse inhibition of the acoustic startle response (PPI)
ACPC did not affect PPI in naive animals (Fig. 5a, F(4.33)=
2.12, NS). There was no interaction between dose and
prepulse intensity: F(8.66)=1.80, NS, but, as expected, a
significant effect of prepulse intensity: F(2.66)=17.90,
P<0.001. One-way ANOVA showed significant differences
in the pulse amplitude: F(4.33)=2.80, P<0.05, and ACPC at
only the single dose of 200 mg/kg increased startle amplitude
as compared with vehicle (Table 2).
Figure 5b shows that ACPC did not affect PPI under
ketamine-disturbed conditions. Two-way ANOVA showed
no significant treatment effect (F(3.24)=1.43, NS and
prepulse intensity: F(2.48)=0.25). The significant interaction
between treatment and prepulse intensity: F(6.48)=3.57,
P<0.01 allowed for performing a post hoc test, which re-
vealed that at an intensity of 73 dB, both vehicle + ketamine
as well as 400 mg/kg of ACPC + ketamine-disrupted PPI,
suggesting a lack of antipsychotic-like activity of ACPC. One-
way ANOVA showed no significant effects of treatment on
pulse amplitude: F(3.24)=0.6, NS (Table 2).
Five-choice serial reaction time task (5-CSRTT)
ACPC affected neither the percentage of accuracy: F(2.29)=
0.52, Fig. 6a nor the number of premature responses:
F(2.29)=0.60, Fig. 6c. Table 3 shows that ACPC did not
affect omissions, correct response latency, reward latency, or
perseverant responses. While MK-801 at relatively low (25–
50 μg/kg) doses did not affect accuracy: F(3.27)=1.03,
Fig. 6b, as expected (Higgins et al. 2003) it dose-
dependently increased the number of premature responses, a
measure of impulsivity: F(3.27)=5.48, P<0.01, Fig. 6d. Con-
sistent with these effects, treatment with MK-801 reduced
correct response latency and reward latency, but did not affect
the number of omissions and perseverant responses (Table 3).
Discussion
The present study demonstrates that ACPC, a partial agonist at
the strychnine-insensitive glycine receptors (Marvizon et al.
1989), facilitates object recognition learning in the novel
Fig. 2 ACPC enhances cognitive flexibility in the attentional set-shifting
test (ASST) in otherwise untreated rats at the dose of 400 but not
200 mg/kg. ***P<0.001 vs. vehicle at the ED phase, #P<0.01 vs.
respective ED phase, N=6 rats per dose. Values represent the mean
(±SEM) number of trials to a given criterion
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object recognition test in both the presence and absence of
NMDAR antagonists, and enhances cognitive flexibility in the
attentional set-shifting task. However, ACPC produced no
measurable effects in PCP-induced hyperactivity, conditioned
avoidance response, and prepulse inhibition tests, suggesting a
lack of antipsychotic-like activity. Like MK-801, ACPC did
not affect accuracy in the five-choice serial reaction time task,
but in contrast to very low doses of MK-801 (Higgins et al.
2003), no increase in impulsivity was observed. The latter
findings strongly suggest prominent differences in the phar-
macological profile of ACPC compared to NMDA channel
blockers. Thus, despite the functional antagonist properties of
ACPC documented in multiple studies, it did not disturb
object recognition learning like PCP and ketamine (Fig. 1),
did not disturb prepulse response like ketamine (Fig. 5), and
did not affect impulsivity like MK-801 (Fig. 6).
Cognition
While an impairment of cognitive flexibility due to NMDAR
blockade has been broadly reported (Stefani et al. 2003;
Egerton et al. 2005; Nikiforuk et al. 2010), much less is known
about the effects of agents enhancing NMDAR-mediated
responses on ASST performance.
Preclinical studies with glycine site ligands demonstrated
procognitive actions of the glycine agonist D-serine (Duffy et al.
2008) and the partial agonist ACPC (Popik and Rygielska 1999)
in the Morris water maze, as well as the partial agonist D-
cycloserine in the radial maze (Pussinen and Sirvio 1999). In
addition, the GlyT1 inhibitor SSR-504734 facilitated working
memory in a continuous delayed alternation task in mice (Singer
et al. 2009). Perhaps more relevant to the present work are the
findings of Shimazaki et al. (2010) demonstrating that the GlyT1
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a bFig. 3 In contrast to clozapine,
which inhibited PCP-induced
hyperactivity (b) at a dose lower
than that producing sedation
(a), ACPC affected neither
spontaneous activity (c) nor PCP-
induced hyperactivity (d). Values
represent the mean (±SEM)
distance traveled, expressed as the
area under the curve (AUC), in
centimeter. Spontaneous activity
was measured for the first 30 min
following drug administration.
PCP-induced hyperactivity was
also measured for 30 min, starting
15 min after PCP administration.
**P<0.01 vs. vehicle control,
#P<0.05 vs. PCP. N=8–9 rats per
dose (clozapine study) and 8–16
rats per dose (ACPC study)
Fig. 4 In the conditioned avoidance response (CAR) test, ACPC affected
neither avoidance responses nor escape failures. In contrast, clozapine (3
and 6, but not 1 mg/kg) selectively inhibited avoidance responses without
affecting escape failures, indicating an antipsychotic-like effect. Values
represent the mean (±SEM) percentage of avoidance responses and
escape failures. **P<0.01, ***P<0.001 vs. vehicle control. N=5–8 rats
per dose (ACPC study) and 10–11 rats per dose (clozapine study)
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inhibitor, NSFP, improved MK-801-disrupted social memory
(Shimazaki et al. 2010) and of Karasawa et al. (2008), who
reported that D-serine and NFPS improved learning in the NOR
test in conditions disturbed byMK-801 administration. The pres-
ent data with ACPC demonstrating a similar alleviation of learn-
ing disturbances induced byPCP and ketamine in the novel object
recognition task, confirm these findings and appear as a logical
consequence of its partial agonistic activity at the glycine/NMDA
sites.
The present results with ACPC also extend, and are consis-
tent with, our recent findings with a GlyT1 inhibitor (Nikiforuk
et al. 2011), demonstrating that increased NMDAR tone may
facilitate cognitive flexibility, which is compromised in schizo-
phrenia (Lewis and Gonzalez-Burgos 2008). Because NMDA
channel blockers produce symptoms of psychoses (Morris et al.
2005) and NMDARs are hypothesized to be hypoactive in
schizophrenia (Coyle et al. 2003), the procognitive effects of
ACPC suggest a potential for this type of compound in treating
the cognitive deficits associated with psychoses.
Antipsychotic-like effects
The rationale for studying the potential antipsychotic-like
effects of a glycine site partial agonist was based on reports
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Fig. 5 In the prepulse inhibition
of the acoustic startle response
(PPI) test, ACPC affected
prepulse inhibition response
neither in (a) naive animals,
suggesting the lack of
psychotomimetic effects, nor in
(b) ketamine-induced PPI dis-
turbed conditions, suggesting the
lack of antipsychotic-like effects.
Values represent the mean
(±SEM) percentage of prepulse
inhibition. *P<0.05, vs. vehicle
control at a given prepulse inten-
sity expressed in decibel.N=4–15
rats per dose (naive animals) and
4–11 rats per dose (ketamine-dis-
turbed conditions)
Table 2 Effects of ACPC, ketamine, and combinations of these com-
pounds on the startle amplitude evoked by a 120-dB pulse tone in rats
Dose of ACPC Mean±SEM (N) startle amplitude in naive rats
0 519.01±75.54 (15)
100 429.87±68.01 (6)
200 911.19±171.42 (7)*
300 580.37±82.44 (6)
400 688.72±98.58 (4)
Treatment Mean±SEM (N) startle amplitude in KET-treated rats
VEH-VEH 557.70±114.42 (6)
KET-VEH 618.38±76.95 (11)
KET-ACPC 200 701.8±138.87 (5)
KET-ACPC 400 763.08±137.65 (6)
*P < 0.05 vs. vehicle
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indicating similar actions of glycine full agonists like D-ser-
ine, the partial agonist D-cycloserine and GlyT1 inhibitors,
already in clinical trials; for a review, see (Harvey and Yee
2013). However, despite using three different tests, we were
unable to demonstrate antipsychotic-like effects of ACPC.
Karcz-Kubicha et al. (1999) reported that ACPC
(600 mg/kg) enhanced PCP-induced hyperactivity; the effects
of lower doses were not investigated. While the lack of efficacy
of ACPC in affecting PCP-induced hyperactivity reported here
could be due to insufficient dosing, doses ≤400mg/kg of ACPC
produced a number of procognitive effects (Figs. 1 and 2; as
well as other therapeutic (antidepressant-like, neuroprotective,
anxiolytic) actions (see the “Introduction” section)).
In apparent contrast to Karcz-Kubicha et al. (1999) and the
present findings, an enhancement of glycine site function
reduces behavioral manifestations associated with NMDA
receptor blockade. For instance, glycine transporter inhibitors
reversed or attenuated NMDAR antagonist-induced deficits in
PPI (Lipina et al. 2005; Depoortere et al. 2005; Boulay et al.
2008), suggesting that stimulation of glycine/NMDA sites
leads to antipsychotic-like effects. This is consistent with
human data showing that ketamine-induced schizophrenia-
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Fig. 6 Neither (a) ACPC nor (b)
MK-801 affected the accuracy in
the five-choice serial reaction
time task (5-CSRTT). However,
while (c) ACPC did not affect the
number of premature responses, a
measure of impulsivity, (d) MK-
801 dose-dependently increased
this measure. Values represent the
mean (±SEM) percentage of
premature responses and number
of premature responses. *P<0.05,
vs. vehicle. N=9−12 rats per dose
(ACPC study) and 7–8 rats per
dose (MK-801 study)
Table 3 Effects of ACPC and MK-801 on omissions (total number of
trials omitted during a 100-trial session), correct response latency (time
from the stimulus onset to a correct response), reward latency (time from
a correct response to the retrieval of food from the magazine), and
perseverant responses (total number of responses emitted after a correct
response has been made) in the five-choice serial reaction time task.
Values represent the mean (±SEM). N=9–12 rats per dose (ACPC study)
and 7–8 rats per dose (MK-801 study)
Treatment Omissions (n) Latency correct (s) Latency reward (s) Perseverant (n)
Vehicle 12.9±2.5 0.96±0.07 1.73±0.08 1.6±0.7
ACPC 200 mg/kg 10.9±1.6 0.99±0.08 1.56±0.13 1.8±0.8
ACPC 400 mg/kg 11.8±1.6 0.81±0.07 1.53±0.11 2.0±0.9
F(2.29)=0.27 F(2.29)=1.85 F(2.29)=0.84 F(2.29)=0.07
NS NS NS NS
Vehicle 13.5±2.6 0.93±0.04 1.80±0.1 3.6±0.8
MK-801 12 μg/kg 8.1±1.8 0.75±0.03* 1.46±0.08* 2.8±1.4
MK-801 25 μg/kg 13.6±2.0 0.78±0.04* 1.47±0.07* 2.3±0.8
MK-801 50 μg/kg 18.0±4.9 0.84±0.04 1.39±0.06* 1.1±0.7
F(3.27)=1.81 F(3.27)=4.25 F(3.27)=4.91 F(3.27)=1.14
NS P<0.05 P<0.01 NS
*P<0.05, vs. vehicle
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like symptoms were ameliorated by GlyT1 inhibitor Org
25935 in healthy humans (D'Souza et al. 2012). In light of
these findings, the lack of efficacy of ACPC in the tests
predictive of antipsychotic action could be viewed as unex-
pected. It should be noted, however, that the present results in
the PPI test should be treated with caution. While a significant
ketamine-induced disruption of PPI was observed (Fig. 5b),
the effects of ketamine were modest compared to other reports
(Swerdlow et al. 1998). ACPC at the highest doses of 300 and
400 mg/kg per se appeared to increase PPI (Fig. 5a), but the
statistical analysis did not find these increases significant.
Nonetheless, such a purportedly antipsychotic-like effect
would not be consistent with the data indicating that neither
clozapine, haloperidol, nor chlorpromazine per se increased
the PPI response (Swerdlow et al. 1998). Finally, ACPC at a
single dose (200 mg/kg) increased startle amplitude, but this
effect was neither related to the dose nor consistent with a
purported antipsychotic-like action, as startle amplitude is
increased by psychotomimetic compounds like MK-801
(Bakshi et al. 1994).
ACPC: from an agonist to a functional antagonist
at the glycine/NMDA sites
In the presence of saturating concentrations of glutamate, the
efficacy of ACPC is high, ~90% relative to glycine (Marvizon
et al. 1989; Karcz-Kubicha et al. 1997). However, ACPC was
reported to exhibit only 60 % of the glycine’s activity in
enhancing [3H]MK-801 binding in the nominal absence of
glutamate (that is, using well-washed brain membranes;
(Marvizon et al. 1989)) suggesting a functional antagonist
profile dependent upon ambient concentrations of both gluta-
mate and glycine.
These findings may have important therapeutic implica-
tions because they suggest that when glutamate concentrations
are high, as in learning and memory tasks (Danysz and Par-
sons 1998), ACPC could display an agonist-like profile, en-
hancing cognitive processes. In contrast, in the hypo-
glutamatergic states associated with psychoses (Coyle et al.
2003), ACPC behaves like a functional glycine receptor an-
tagonist and exhibits no antipsychotic-like efficacy.
Clinical studies are consistent with this hypothesis. Thus,
while an addition of the partial agonist, D-cycloserine, to
risperidone in schizophrenic patients reduced negative symp-
toms (Evins et al. 2002), meta-analyses showed that glycine
site full agonists are more effective than D-cycloserine in
improving the overall psychopathology in schizophrenic
patients receiving antipsychotic drugs (Heresco-Levy
and Javitt 2004; Tuominen et al. 2005; Tsai and Lin
2010). Nonetheless, the recent reports indicating that
GlyT1 inhibitors do not improve clinical symptoms of
schizophrenia in large, phase III trials (Kingwell 2014) raise
serious questions about the viability of glutamate-based
approaches to treat schizophrenia. At a minimum, these dis-
crepant findings indicate that not all methods of elevating
glycinergic tone produce equivalent results in the clinic. In
essence, this raises the bar for preclinical evidence sufficient to
trigger clinical studies. Nonetheless, likeNMDAR antagonists
(Layer et al. 1998), D-cycloserine at relatively high doses,
suggestive of NMDAR antagonistic actions, was recently
reported to produce an antidepressant effect in treatment-
resistant depressed patients (Heresco-Levy et al. 2013). These
clinical observations reveal the potential for glycine site partial
agonists to mimic the pharmacological actions of both glycine
site agonists and antagonists, which is consistent with the
present demonstration that ACPC possesses procognitive,
but not antipsychotic-like efficacy. Thus, we postulate that a
compound with a neurochemical profile like that of ACPC
may represent a useful pharmacological approach for cogni-
tive enhancement in domains critically affected in schizophre-
nia, but would not affect negative or positive symptoms of the
psychoses.
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